Literature DB >> 10557408

The cost of Alzheimer's disease in managed care: a cross-sectional study.

J Leon1, P J Neumann.   

Abstract

BACKGROUND: The number of people with Alzheimer's disease (AD) is expected to grow as the US population ages. Given the increasing enrollment in managed care organizations, growth in the number of managed care patients with AD is a certainty. To our knowledge, no study to date has focused on the cost of care of community-dwelling AD patients receiving care through a health maintenance organization (HMO) system.
METHODS: One hundred and fifty patients were recruited from 4 managed care sites from July through December 1996. Staff at each site clinically confirmed patients' AD diagnosis, AD severity, and ascertained patients' comorbidities. Demographic, quality of life, and service utilization data were collected from proxy respondents. Costs of hospitalization, medications, doctor visits (formal costs), and caregiver assistance (informal costs) were analyzed separately.
RESULTS: The average total (formal and informal) per-patient costs in the 4 settings in 1996 were $18,804. Costs increased with cognitive impairment. For patients with mild, moderate, and severe AD, annual total costs were $14,904, $19,272, and $25,860, respectively. Annual direct costs were $5520, $7044 and $10,992, respectively.
CONCLUSION: Across all severity levels, we calculated a total annual cost of $8.8 billion for managed care enrollees older than 65 years in the United States. We did not estimate these costs for the population younger than 65 years because of the variability in AD prevalence estimates. Due to the increased costs for patients with more severe AD, interventions that would reverse or delay progression may result in significant cost savings.

Entities:  

Mesh:

Year:  1999        PMID: 10557408

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  15 in total

Review 1.  Dementia case management effectiveness on health care costs and resource utilization: a systematic review of randomized controlled trials.

Authors:  C Pimouguet; T Lavaud; J F Dartigues; C Helmer
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

Review 2.  Alzheimer's disease: the strength of association of costs with different measures of disease severity.

Authors:  J Mauskopf; J Racketa; E Sherrill
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

Review 3.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 4.  A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada.

Authors:  Mark Oremus; S Carolina Aguilar
Journal:  Pharmacoeconomics       Date:  2011-02       Impact factor: 4.981

5.  Relationship between global severity of patients with Alzheimer's disease and costs of care in Spain; results from the co-dependence study in Spain.

Authors:  J Darbà; L Kaskens; L Lacey
Journal:  Eur J Health Econ       Date:  2014-10-28

6.  Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease.

Authors:  Katherine A Lyseng-Williamson; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

7.  Cost of dementia in Medicare managed care: a systematic literature review.

Authors:  Paul Fishman; Norma B Coe; Lindsay White; Paul K Crane; Sungchul Park; Bailey Ingraham; Eric B Larson
Journal:  Am J Manag Care       Date:  2019-08-01       Impact factor: 2.229

8.  Healthcare utilization and costs in primary care patients with dementia: baseline results of the DelpHi-trial.

Authors:  Bernhard Michalowsky; Steffen Flessa; Tilly Eichler; Johannes Hertel; Adina Dreier; Ina Zwingmann; Diana Wucherer; Henriette Rau; Jochen René Thyrian; Wolfgang Hoffmann
Journal:  Eur J Health Econ       Date:  2017-02-03

9.  Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective.

Authors:  Roy W Jones; Paul McCrone; Chantal Guilhaume
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 10.  The prevalence, cost implications, and management of sleep disorders: an overview.

Authors:  Jamil L Hossain; Colin M Shapiro
Journal:  Sleep Breath       Date:  2002-06       Impact factor: 2.816

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.